P. Meyers, R. Gorlick, and . Osteosarcoma, OSTEOSARCOMA, Pediatric Clinics of North America, vol.44, issue.4, pp.973-89, 1997.
DOI : 10.1016/S0031-3955(05)70540-X

P. Picci, Osteosarcoma (osteogenic sarcoma), Orphanet Journal of Rare Diseases, vol.2, issue.1, p.6, 2007.
DOI : 10.1186/1750-1172-2-6

S. Bielack, B. Kempf-bielack, and G. Delling, Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols, Journal of Clinical Oncology, vol.20, issue.3, pp.776-90, 2002.
DOI : 10.1200/JCO.2002.20.3.776

M. Link, A. Goorin, and A. Miser, The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity, New England Journal of Medicine, vol.314, issue.25, pp.1600-1606, 1986.
DOI : 10.1056/NEJM198606193142502

P. Meyers, G. Heller, and J. Healey, Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience., Journal of Clinical Oncology, vol.10, issue.1, pp.5-15, 1992.
DOI : 10.1200/JCO.1992.10.1.5

M. Harris, A. Cantor, and A. Goorin, Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A pediatric oncology group study, Medical and Pediatric Oncology, vol.84, issue.2, pp.87-92, 1995.
DOI : 10.1002/mpo.2950240205

F. Kung, C. Pratt, and R. Vega, Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study, Cancer, vol.9, issue.5, pp.1898-903, 1993.
DOI : 10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q

J. Miser, T. Kinsella, and T. Triche, Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults., Journal of Clinical Oncology, vol.5, issue.8, pp.1191-1199, 1987.
DOI : 10.1200/JCO.1987.5.8.1191

P. Meyers, C. Schwartz, and M. Krailo, Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, Journal of Clinical Oncology, vol.23, issue.9, pp.2004-2015, 2005.
DOI : 10.1200/JCO.2005.06.031

P. Anderson, Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma, Future Oncology, vol.2, issue.3, pp.333-376, 2006.
DOI : 10.2217/14796694.2.3.333

D. Hawkins and C. Arndt, Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy, Cancer, vol.5, issue.11, pp.2447-56, 2003.
DOI : 10.1002/cncr.11799

G. Bacci and L. S. , Adjuvant and neoadjuvant chemotherapy in osteosarcoma, Chir Organi Mov, vol.86, pp.253-68, 2001.

P. Meyers, Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma, Expert Review of Anticancer Therapy, vol.9, issue.8, pp.1035-1084, 2009.
DOI : 10.1586/era.09.69

P. Meyers, C. Schwartz, and M. Krailo, Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival???A Report From the Children's Oncology Group, Journal of Clinical Oncology, vol.26, issue.4, pp.633-641, 2008.
DOI : 10.1200/JCO.2008.14.0095

K. Mori, K. Ando, and D. Heymann, Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Review of Anticancer Therapy, vol.8, issue.2, pp.151-160, 2008.
DOI : 10.1586/14737140.8.2.151

P. Anderson, L. Kopp, and N. Anderson, Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma), Expert Opinion on Investigational Drugs, vol.5, issue.11, pp.1703-1718, 2008.
DOI : 10.1083/jcb.124.4.619

D. Hughes, Novel agents in development for pediatric sarcomas, Current Opinion in Oncology, vol.21, issue.4, pp.332-339, 2009.
DOI : 10.1097/CCO.0b013e32832c94e2

A. Nardin, M. Lefebvre, and K. Labroquere, Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma, Current Cancer Drug Targets, vol.6, issue.2, pp.123-156, 2006.
DOI : 10.2174/156800906776056473

W. Fogler and I. Fidler, Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes, International Journal of Immunopharmacology, vol.9, issue.2, pp.141-50, 1987.
DOI : 10.1016/0192-0561(87)90088-9

A. Schroit and I. Fidler, Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases, Prog Clin Biol Res, vol.102, pp.347-55, 1982.

E. Kleinerman, K. Erickson, and A. Schroit, Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide, Cancer Res, vol.43, pp.2010-2014, 1983.

W. Fogler and I. Fidler, Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages, Cancer Res, vol.45, pp.14-22, 1985.

E. Galligioni, M. Quaia, and A. Spada, Activation of cytolytic activity in peripheral blood, International Journal of Cancer, vol.43, issue.3, pp.380-385, 1993.
DOI : 10.1002/ijc.2910550307

T. Asano, A. Mcwatters, and T. An, Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes, J Pharmacol Exp Ther, vol.268, pp.1032-1041, 1994.

I. Kurzman, F. Shi, and D. Vail, Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells, Cancer Biotherapy & Radiopharmaceuticals, vol.14, issue.2, pp.121-129, 1999.
DOI : 10.1089/cbr.1999.14.121

P. Dieter, P. Ambs, and E. Fitzke, Comparative studies of cytotoxicity and the release of TNF-alpha, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE, J Immunol, vol.155, pp.2595-604, 1995.

E. Macewen, I. Kurzman, and D. Vail, Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor, Clin Cancer Res, vol.5, pp.4249-58, 1999.

T. Asano, B. Mcintyre, and J. Bednarczyk, Liposomal muramyl tripeptide upregulates 20 adhesion molecules on the surface of human monocytes, Oncol Res, vol.7, pp.253-260, 1995.

W. Fogler, R. Wade, and D. Brundish, Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice, J Immunol, vol.135, pp.1372-1379, 1985.

S. Cryan, Carrier-based strategies for targeting protein and peptide drugs to the lungs, The AAPS Journal, vol.7, issue.1
DOI : 10.1208/aapsj070104

W. Zamboni, Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents, Clinical Cancer Research, vol.11, issue.23
DOI : 10.1158/1078-0432.CCR-05-1895

B. Gay, J. Cardot, and C. Schnell, Comparative Pharmacokinetics of Free Muramyl Tripeptide Phosphatidyl Ethanolamine (MTP-PE) and Liposomal MTP-PE, Journal of Pharmaceutical Sciences, vol.82, issue.10, pp.997-1001, 1993.
DOI : 10.1002/jps.2600821005

J. Murray, E. Kleinerman, and J. Cunningham, Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients., Journal of Clinical Oncology, vol.7, issue.12, pp.1915-1940, 1989.
DOI : 10.1200/JCO.1989.7.12.1915

P. Dieter, U. Hempel, and S. Kamionka, Prostaglandin E2 Affects Differently the Release of Inflammatory Mediators from Resident Macrophages by LPS and Muramyl Tripeptides, Mediators of Inflammation, vol.8, issue.6
DOI : 10.1080/09629359990306

E. Macewen, I. Kurzman, and R. Rosenthal, Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide, JNCI Journal of the National Cancer Institute, vol.81, issue.12, pp.935-943, 1989.
DOI : 10.1093/jnci/81.12.935

E. Kleinerman, J. Snyder, and N. Jaffe, Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma., Journal of Clinical Oncology, vol.9, issue.2, pp.259-67, 1991.
DOI : 10.1200/JCO.1991.9.2.259

I. Fidler, N. Brown, and I. Hart, Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously, J Biol Response Mod, vol.4, pp.298-309, 1985.

I. Fidler, J. Jessup, and W. Fogler, Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma, Cancer Res, vol.46, pp.994-1002, 1986.

S. Sone, T. Utsugi, and P. Tandon, Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients, Cancer Immunology Immunotherapy, vol.35, issue.6, pp.357-62, 1990.
DOI : 10.1007/BF01786885

C. Dinney, S. Tanguay, and C. Bucana, Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice, J Interferon Cytokine Res, vol.15, pp.585-92, 1995.

I. Fidler, D. Fan, and Y. Ichinose, Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma, Invasion Metastasis, vol.9, pp.75-88, 1989.

P. Goldbach, S. Dumont, and R. Kessler, In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide, Am J Physiol, vol.270, pp.429-463, 1996.

T. Utsugi, A. Nii, and D. Fan, Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages, Cancer Immunology, Immunotherapy, vol.55, issue.5, pp.285-92, 1991.
DOI : 10.1007/BF01756592

S. Sone, P. Tandon, and T. Utsugi, Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes, International Journal of Cancer, vol.4, issue.4, pp.495-500, 1986.
DOI : 10.1002/ijc.2910380407

E. Kleinerman, J. Murray, and J. Snyder, Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine, Cancer Res, vol.49, pp.4665-70, 1989.

E. Kleinerman, S. Jia, and J. Griffin, Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration., Journal of Clinical Oncology, vol.10, issue.8, pp.1310-1316, 1992.
DOI : 10.1200/JCO.1992.10.8.1310

J. Talmadge, M. Schneider, and M. Collins, Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE, J Immunol, vol.135, pp.1477-83, 1985.

Z. Xu and I. Fidler, The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide, Cancer Immunology Immunotherapy, vol.18, issue.2
DOI : 10.1007/BF00205745

B. Smith, I. Kurzman, and K. Schultz, Cytostatic Activity of Canine Plastic-Adherent Mononuclear Cells Against Canine Osteosarcoma Cells, Cancer Biotherapy, vol.8, issue.2, pp.137-181, 1993.
DOI : 10.1089/cbr.1993.8.137

S. Bielack, B. Kempf-bielack, and D. Schwenzer, Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremit??ten, Klinische P??diatrie, vol.211, issue.04, pp.260-70, 1999.
DOI : 10.1055/s-2007-1019701

E. Kleinerman, P. Meyers, and A. Raymond, Combination Therapy with Ifosfamide and Liposome-Encapsulated Muramyl Tripeptide, Journal of Immunotherapy, vol.17, issue.2, pp.181-93, 1995.
DOI : 10.1097/00002371-199504000-00007

J. Killion, E. Kleinerman, and M. Wilson, Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents, Oncol Res, vol.4, pp.413-421, 1992.

A. Provisor, L. Ettinger, and J. Nachman, Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group., Journal of Clinical Oncology, vol.15, issue.1, pp.76-84, 1997.
DOI : 10.1200/JCO.1997.15.1.76

S. Hunsberger, B. Freidlin, and M. Smith, Complexities in Interpretation of Osteosarcoma Clinical Trial Results, Journal of Clinical Oncology, vol.26, issue.18, pp.3103-3107, 2008.
DOI : 10.1200/JCO.2008.17.3484

S. Bielack, N. Marina, and S. Ferrari, Osteosarcoma: The Same Old Drugs or More?, Journal of Clinical Oncology, vol.26, issue.18, pp.3102-3105, 2008.
DOI : 10.1200/JCO.2008.17.1108

A. Goorin, M. Harris, and M. Bernstein, Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial, Journal of Clinical Oncology, vol.20, issue.2, pp.426-459, 2002.
DOI : 10.1200/JCO.2002.20.2.426

A. Chou, P. Merola, and L. Wexler, Treatment of osteosarcoma at first recurrence after contemporary therapy, Cancer, vol.61, issue.10, pp.2214-2235, 2005.
DOI : 10.1002/cncr.21417

E. Lafleur, N. Koshkina, and J. Stewart, Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells, Clinical Cancer Research, vol.10, issue.23, pp.8114-8123, 2004.
DOI : 10.1158/1078-0432.CCR-04-0353

W. Urba, L. Hartmann, and D. Longo, Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine, Cancer Res, vol.50, pp.2979-86, 1990.

P. Creaven, J. Cowens, and D. Brenner, Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer, J Biol Response Mod, vol.9, pp.492-500, 1990.

E. Kleinerman, J. Gano, and D. Johnston, Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma, American Journal of Clinical Oncology, vol.18, issue.2, pp.93-102, 1995.
DOI : 10.1097/00000421-199504000-00001

W. Fujimaki, J. Griffin, and E. Kleinerman, Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?, Cancer Immunology Immunotherapy, vol.83, issue.1, pp.45-51, 1993.
DOI : 10.1007/BF01789130

P. Fedorocko, Z. Hoferova, and M. Hofer, Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities, Neoplasma, vol.50, pp.176-84, 2003.

E. Kleinerman, A. Raymond, and C. Bucana, Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid), Cancer Immunology Immunotherapy, vol.66, issue.A, pp.211-231, 1992.
DOI : 10.1007/BF01741788